Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05331599 · ClinicalTrials.gov registry record
Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-Life Depression
A clinical trial of Cognitive Dysfunction and Recurrence, sponsored by University of Illinois at Chicago.
- Active
- Registry status
- 210
- Enrollment target
- 1
- Study location
NCT05331599: Active study of Cognitive Dysfunction and Recurrence, sponsored by University of Illinois at Chicago.
NCT05331599 is a study of Cognitive Dysfunction and Recurrence that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 210 participants, below the 1,988-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05331599, a study of Cognitive Dysfunction and Recurrence, is active but no longer recruiting, sponsored by University of Illinois at Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
Late-life depression (LLD) is associated with disability, increased risk for cognitive decline and dementia, elevated suicide risk, and greater all-cause mortality. These outcomes are related to depression being a recurrent disorder, with repeated episodes over a patient's lifetime. Recurrence rates (defined as including both relapse and recurrence) are high in LLD. The goals of this study are to identify neurobiological factors that predict recurrence risk, and examine how cognitive performance changes are both influenced by these neurobiological factors and also predict recurrence risk.
Primary Outcome
Stress reactivity measured experimentally (neural reactivity during fMRI stress induction task) and ecologically (affective instability by ecological momentary assessment).
Conditions Studied
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2026-01-15 |
What the registry record for NCT05331599 still lists
NCT05331599 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 1,988-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 0 interventions.
NCT05331599 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05331599 about?
NCT05331599 is a clinical study titled "Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-Life Depression". Late-life depression (LLD) is associated with disability, increased risk for cognitive decline and dementia, elevated suicide risk, and greater all-cause mortality. These outcomes are related to depression being a recurrent disorder, with repeated episodes over a patient's lifetime. Recurrence rates...
What is the current status of trial NCT05331599?
This trial is currently active not recruiting. The enrollment target is 210 participants. The study started on 2020-06-01. Estimated completion is 2026-01-15.
What conditions does trial NCT05331599 study?
This clinical trial studies the following conditions: Cognitive Dysfunction, Recurrence, Depression in Old Age.
Who is sponsoring clinical trial NCT05331599?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05331599 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05331599's enrollment target sits among peer trials
210 14th of 45 higher than 32 of 45 other Cognitive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI